Company Overview

Celularity Inc. is a publicly traded biotechnology company focused on developing and commercializing placenta-derived cell therapies and related biomaterials. The company operates within the regenerative medicine, cell therapy, and biopharmaceutical manufacturing industries, with a core emphasis on allogeneic cell products derived from the postpartum human placenta. Its technology platform is designed to leverage the biological properties of placental cells to address unmet needs in oncology, inflammatory diseases, and degenerative conditions.

The company’s primary revenue drivers have historically included research collaborations, licensing arrangements, and early-stage commercialization of biomaterials, while its therapeutic pipeline remains largely in clinical development. Celularity positions itself uniquely through its access to a large-scale, ethically sourced placental cell supply and vertically integrated manufacturing capabilities. Founded in 2017, the company evolved from earlier academic and clinical research initiatives and became publicly listed in 2021 through a merger transaction, transitioning from a private development-stage biotechnology firm to a publicly traded entity.

Business Operations

Celularity’s operations are organized around cell therapy development, biomaterials, and biosourcing activities, with revenue generation primarily tied to development programs, grant income, and limited commercial sales. Its core business units include regenerative medicine programs, oncology-focused cell therapies, and placenta-derived biomaterials, which are supported by proprietary cell isolation, expansion, and cryopreservation technologies. The company controls manufacturing and processing assets intended to support both internal clinical pipelines and potential third-party collaborations.

Operations are primarily based in the United States, with clinical development conducted through U.S.-based research institutions and contract research organizations. Celularity maintains subsidiaries that support manufacturing, intellectual property management, and research activities, including Celularity Manufacturing USA, Inc. The company has also entered into strategic research and clinical partnerships with academic medical centers to advance its therapeutic candidates.

Strategic Position & Investments

Celularity’s strategic direction centers on advancing late preclinical and early clinical-stage cell therapy candidates while monetizing non-core assets and biomaterials to support liquidity. Growth initiatives have included expanding its placental cell therapy pipeline in oncology and inflammatory diseases, as well as pursuing out-licensing and collaboration opportunities to offset development costs. The company has publicly disclosed efforts to streamline operations and prioritize programs with clearer regulatory and commercial pathways.

Investment activity has focused on internal research and development rather than large-scale acquisitions. Notable strategic assets include wholly owned subsidiaries supporting manufacturing and biosourcing, as well as investments in emerging cell therapy technologies derived from placental biology. While the company has announced restructuring and cost-containment measures, long-term strategic outcomes remain dependent on clinical trial progress and capital availability; where projections vary, data is inconclusive based on available public sources.

Geographic Footprint

Celularity is headquartered in the United States, with its principal executive offices and core research and manufacturing activities located domestically. The company’s operational footprint is primarily concentrated in North America, reflecting its focus on U.S. regulatory pathways and clinical trial infrastructure. Manufacturing and biosourcing facilities are designed to serve domestic development needs, with limited current commercial distribution outside the U.S.

Internationally, Celularity’s presence is mainly indirect, consisting of research collaborations, clinical trial participation, and intellectual property coverage rather than large-scale physical operations. The company has indicated interest in global markets for future commercialization, but material international revenue generation has not yet been established based on publicly available disclosures.

Leadership & Governance

Celularity was founded by Robert J. Hariri, who has played a central role in shaping the company’s scientific and strategic vision. Leadership emphasizes translational science, vertically integrated manufacturing, and disciplined capital allocation in a capital-intensive biotechnology environment. Governance follows a conventional public-company structure with a board of directors overseeing management and strategic execution.

Key executives include:

• Robert J. Hariri – Chairman and Chief Executive Officer
• Andrew Pecora – Chief Innovation Officer and President, R&D
• James Brady – Chief Financial Officer

Certain executive titles and responsibilities have evolved over time; where disclosures differ across reporting periods, role descriptions are based on the most consistently reported public filings, and some data remains inconclusive based on available public sources.